EGFR (K728A/T790M/C797S/L858R)

EGFR · Variant type: point · HGVS: p.R999A

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gilteritinib	94.2%	5.8%	88.97
2	Pacritinib	92.0%	8.0%	88.64
3	Neratinib	78.9%	21.1%	93.18
4	Lazertinib	68.8%	31.2%	97.47
5	Canertinib	68.8%	31.2%	96.49
6	Erlotinib	56.3%	43.7%	99.75
7	Deucravacitinib	55.5%	44.5%	98.99
8	Vandetanib	51.9%	48.1%	95.74
9	Mobocertinib	50.2%	49.8%	97.22
10	Entrectinib	43.3%	56.7%	93.69
11	Fedratinib	39.5%	60.5%	96.21
12	Defactinib	36.7%	63.3%	92.68
13	Pralsetinib	32.5%	67.5%	93.43
14	Abemaciclib	31.4%	68.6%	91.48
15	Pirtobrutinib	29.7%	70.3%	99.49
16	Repotrectinib	21.6%	78.4%	84.21
17	Tivozanib	21.3%	78.7%	92.42
18	Sunitinib	14.5%	85.5%	91.73
19	Erdafitinib	13.6%	86.4%	95.71
20	Avapritinib	12.7%	87.3%	97.73
21	Selpercatinib	12.6%	87.4%	96.72
22	Tepotinib	8.8%	91.2%	99.75
23	Darovasertib	7.5%	92.5%	96.99
24	Capivasertib	7.1%	92.9%	96.48
25	Palbociclib	7.0%	93.0%	98.75

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gilteritinib	94.2%	91.0%	+3.1%
Pacritinib	92.0%	—	—
Neratinib	78.9%	100.0%	-21.1%
Lazertinib	68.8%	100.0%	-31.2%
Canertinib	68.8%	98.4%	-29.6%
Erlotinib	56.3%	99.4%	-43.1%
Deucravacitinib	55.5%	—	—
Vandetanib	51.9%	99.3%	-47.4%
Mobocertinib	50.2%	100.0%	-49.8%
Entrectinib	43.3%	—	—
Fedratinib	39.5%	—	—
Defactinib	36.7%	94.6%	-57.9%
Pralsetinib	32.5%	99.1%	-66.7%
Abemaciclib	31.4%	—	—
Pirtobrutinib	29.7%	—	—
Repotrectinib	21.6%	—	—
Tivozanib	21.3%	—	—
Sunitinib	14.5%	—	—
Erdafitinib	13.6%	—	—
Avapritinib	12.7%	—	—
Selpercatinib	12.6%	—	—
Tepotinib	8.8%	—	—
Darovasertib	7.5%	—	—
Capivasertib	7.1%	—	—
Palbociclib	7.0%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.6ms